Anil Shah
Cardiovascular Disease · Hollywood, MDNPI 1730108069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,187 and has fallen 59.7% since, to $479 in 2025.
Across 215 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$566
- Merck$531
- Amgen$491
- E.r. Squibb & Sons, L.L.C.$408
- Pfizer$385
- Boehringer Ingelheim$309
- plus $2K from 22 others
Across 14 payments — averaging $5573.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$78K
What the payments were for
- Speaking & faculty fees$3257%
- Food & beverage$4,12792%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $566 |
| Merck | 27 | $531 |
| Amgen | 29 | $491 |
| E.r. Squibb & Sons, L.L.C. | 22 | $408 |
| Pfizer | 23 | $385 |
| Boehringer Ingelheim | 12 | $309 |
| Medtronic | 5 | $307 |
| Sanofi-aventis U.S. LLC | 15 | $228 |
| Vifor Pharma, Inc. | 1 | $200 |
| Atricure, Inc. | 7 | $173 |
| Johnson & Johnson | 8 | $142 |
| AstraZeneca | 7 | $140 |
| Sanofi | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $110 |
| Boston Scientific | 3 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $54 |
| Bayer | 2 | $38 |
| Lilly USA, LLC | 1 | $29 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
- MULTAQ$125
- CoreValve Evolut$116
How this compares
$4,472 in reported general payments places this provider in the 70th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 386 | $491,937 |
| EntrestoSacubitril/Valsartan | 103 | $143,997 |
| MultaqDronedarone Hcl | 42 | $81,534 |
| XareltoRivaroxaban | 51 | $74,424 |
| Rosuvastatin Calcium | 386 | $7,427 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $7,046 |
| Metoprolol Succinate | 376 | $6,822 |
| BrilintaTicagrelor | 11 | $5,754 |
| Candesartan Cilexetil | 63 | $5,392 |
| Nifedipine ErNifedipine | 136 | $5,225 |
| Ranolazine ErRanolazine | 54 | $4,673 |
| Atorvastatin Calcium | 304 | $3,816 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 91 | $3,147 |
| Amiodarone Hcl | 69 | $2,494 |
| Ezetimibe | 79 | $2,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $385 | $491,937386 claims |
| NovartisEntresto | $566 | $143,997103 claims |
| Sanofi-aventis U.S. LLCMultaq | $228 | $81,53442 claims |
| Johnson & JohnsonXarelto | $142 | $74,42451 claims |
| AstraZenecaBrilinta | $140 | $5,75411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Hollywood
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Mark HaigneyBethesda$121K
- Charles CummingsBaltimore$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.